UBS Group
FBLG icon

UBS Group’s FibroBiologics FBLG Stock Holding History

UBS Group’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02K Sell
1,073
-4,648
-81% -$5.4K ﹤0.01% 9653
2026
Q1 		$7.55K Sell
5,721
-318
-5% -$1.89K ﹤0.01% 8567
2025
Q4 		$27.2K Buy
6,039
+2,167
+56% +$15.3K ﹤0.01% 7587
2025
Q3 		$42.3K Sell
3,872
-1,642
-30% -$19.7K ﹤0.01% 7685
2025
Q2 		$68.6K Sell
5,514
-129
-2% -$2.33K ﹤0.01% 7524
2025
Q1 		$102K Sell
5,643
-767
-12% -$21.9K ﹤0.01% 7037
2024
Q4 		$256K Buy
6,410
+4,242
+196% +$228K ﹤0.01% 6305
2024
Q3 		$134K Sell
2,168
-1,735
-44% -$115K ﹤0.01% 6155
2024
Q2 		$389K Buy
3,903
+3,902
+390,200% +$744K ﹤0.01% 5192
2024
Q1 		$303 Buy
+1
New +$240 ﹤0.01% 8638

Other funds holding FBLG

CFP
Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return
FEG
Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group's FBLG Position: Q2 2026 in Review

UBS Group reduced its FibroBiologics (FBLG) stake by 81% in Q2 2026, selling an estimated $5.4K and leaving 1,073 shares worth $1.02K. The position accounts for ﹤0.01% of the portfolio, ranked #9653.

UBS Group first reported a position in FBLG in Q1 2024 and has held it in 10 quarters since. The position peaked at $389K in Q2 2024. 16 funds tracked by Wall St. Rank hold FBLG as of Q2 2026.

  • UBS Group held 1,073 shares of FibroBiologics worth $1.02K as of Q2 2026.
  • UBS Group sold 4,648 FibroBiologics shares in Q2 2026, an estimated $5.4K.
  • FibroBiologics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9653 holding.
  • UBS Group first reported a position in FibroBiologics in Q1 2024 and has held it in 10 quarters since.
  • UBS Group's FibroBiologics position peaked at $389K in Q2 2024.
  • 16 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.